Literature DB >> 15735685

The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue.

Ilaria Le Pera1, Rodolfo Iuliano, Tullio Florio, Christiane Susini, Francesco Trapasso, Massimo Santoro, Lorenzo Chiariotti, Gennaro Schettini, Giuseppe Viglietto, Alfredo Fusco.   

Abstract

The expression of the receptor protein tyrosine phosphatase r-PTPeta is drastically reduced in rat and human malignant thyroid cells, whereas its restoration reverts the neoplastic phenotype of retrovirally transformed rat thyroid cells. Moreover, reduced levels and loss of heterozygosity of DEP-1, the human homolog of r-PTPeta, have been found in many human neoplasias. Here, we report that the r-PTPeta protein binds to c-Src in living cells and dephosphorylates the c-Src inhibitory tyrosine phosphorylation site (Tyr 529), thereby increasing c-Src tyrosine kinase activity in malignant rat thyroid cells stably transfected with r-PTPeta. Tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin was enhanced in r-PTPeta-expressing cells. This was associated with increased adhesion of malignant r-PTPeta-transfected thyroid cells vs both untransfected cells and cells stably transfected with an inactive r-PTPeta mutant. Treatment of rat thyroid cells with the c-Src inhibitor PP2 decreased cell adhesion to a higher extent in r-PTPeta-transfected cells than in mock-transfected or stably transfected cells with the inactive r-PTPeta mutant, indicating that r-PTPeta regulates cell-substratum adhesion by activating c-Src. Interestingly, the extent of both c-Src dephosphorylation at Tyr 529, FAK and paxillin phosphorylation, and the increased cell adhesion were associated with the degree of r-PTPeta expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735685     DOI: 10.1038/sj.onc.1208510

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Low-resolution structure and fluorescence anisotropy analysis of protein tyrosine phosphatase eta catalytic domain.

Authors:  Huita C Matozo; Maria A M Santos; Mario de Oliveira Neto; Lucas Bleicher; Luís Mauricio T R Lima; Rodolfo Iuliano; Alfredo Fusco; Igor Polikarpov
Journal:  Biophys J       Date:  2007-03-30       Impact factor: 4.033

2.  Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.

Authors:  Keiko Takahashi; Rachel H Kim; Lejla Pasic; Lilly He; Shinya Nagasaka; Daisuke Katagiri; Tracy May; Akira Shimizu; Raymond C Harris; Raymond L Mernaugh; Takamune Takahashi
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

3.  Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.

Authors:  Jun Mori; Zoltan Nagy; Giada Di Nunzio; Christopher W Smith; Mitchell J Geer; Rashid Al Ghaithi; Johanna P van Geffen; Silke Heising; Luke Boothman; Bibian M E Tullemans; Joao N Correia; Louise Tee; Marijke J E Kuijpers; Paul Harrison; Johan W M Heemskerk; Gavin E Jarvis; Alexander Tarakhovsky; Arthur Weiss; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

4.  Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Authors:  Yiru Xu; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2012-08-01       Impact factor: 5.782

Review 5.  Similarities and differences in the regulation of leukocyte extravasation and vascular permeability.

Authors:  Dietmar Vestweber; Florian Wessel; Astrid Fee Nottebaum
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

6.  Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice.

Authors:  Zoltan Nagy; Jun Mori; Vanesa-Sindi Ivanova; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

Review 7.  CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Authors:  Michelle L Hermiston; Julie Zikherman; Jing W Zhu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis.

Authors:  Gabi Tarcic; Shlomit K Boguslavsky; Jean Wakim; Tai Kiuchi; Angela Liu; Felicia Reinitz; David Nathanson; Takamune Takahashi; Paul S Mischel; Tony Ng; Yosef Yarden
Journal:  Curr Biol       Date:  2009-11-17       Impact factor: 10.834

9.  Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.

Authors:  Francesca Sacco; Michele Tinti; Anita Palma; Emanuela Ferrari; Aurelio P Nardozza; Rob Hooft van Huijsduijnen; Takamune Takahashi; Luisa Castagnoli; Gianni Cesareni
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

10.  Reconciling the roles of FAK in osteoblast differentiation, osteoclast remodeling, and bone regeneration.

Authors:  Jae-Beom Kim; Philipp Leucht; Cynthia A Luppen; Yu Jin Park; Hilary E Beggs; Caroline H Damsky; Jill A Helms
Journal:  Bone       Date:  2007-03-13       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.